TP53 and endometrioid adenocarcinoma: In the second time period, 30% of the Cre:ER+/−; Ptenf/f; p53+/+, Cre:ER+/−; Ptenf/f; p53f/+ and Cre:ER+/−; Ptenf/f; p53f/f mice developed complex hyperplasia, while 50%–55% of the mice displayed hyperplasia with complex atypia and endometrioid adenocarcinomas limited to the endometrium.